

☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *						2. Issuer Name and Ticker or Trading Symbol								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
Zhang Jack Y.						Amphastar Pharmaceuticals, Inc. [AMPH]							_X_ Director		_X_ 10	% Owner	
(Last)	(First)	(Mi	ddle)		3. I	Date	of Earl	iest Trans	actio	n (MM/I	DD/YYYY)	_X_ Officer (gi			her (specify	below)
C/O AMPHASTAR PHARMACEUTICALS, INC., 11570 6TH STREET						3/16/2023											
(Street) RANCHO CUCAMONGA,, CA 91730						4. If Amendment, Date Original Filed (MM/DD/YYYY)								6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person			
						le 10	h5-1(c)) Transact	ion I	ndicatio	nn .		X Form filed	by More than	One Reporting	g Person	
(City) (State) (Zip)					Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.												
			Table	: I - N	on-Der	ivati	ive Sec	urities A	quir	red, Dis	posed o	f, or I	Beneficially Own	ed			
1. Title of Security (Instr. 3) 2. Trans				2A. Deemed Execution Date, if any		3. Trans. Code (Instr. 8)		4. Securities Acqui or Disposed of (D) (Instr. 3, 4 and 5)		red (A)	(Instr. 3 and 4) Forn Direction		6. Ownership Form: Direct (D) or Indirect	Beneficial Ownership			
								Code	V	Amoun	(A) or (D)	Price				(I) (Instr. 4)	,
Common Stock				3/16	5/2023			G		57365	D	\$0.00		0		I	See footnote (1)
Common Stock				3/16	5/2023			G		57365	D	\$0.00		0		I	See footnote (2)
Common Stock				3/16	5/2023			F		25241	<u>D</u>	\$37.60	20	94486 ⁽⁴⁾		D	
Common Stock 3/16/202				5/2023			F		9998 (3). D	\$37.60	14	1462654 (5)			See footnote (6)	
Common Stock 3/17/202.				7/2023	F 15768 (2) D \$36.29 2078718				D								
Common Stock 3/17/202.				7/2023	F 7052 (3) D \$36.29 1455602					I	See footnote (6)						
Common Stock													6	827679		I	See footnote (7)
Common Stock													5000		I	See footnote (8)	
	Tab	le II - Der	ivativ	e Sec	urities l	Bene	eficially	Owned	(e.g.,	, puts, o	calls, wa	rrant	s, options, conve	rtible secu	ırities)		
1. Title of Derivate Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Trans. Date Execution Date, if any (Instr. 3)		4. Trans. (Instr. 8)	rans. Code r. 8) 5. Num Derivat Acquire Dispose (Instr. 3		ber of ive Securities and (A) or and of (D) , 4 and 5)		Date Exer d Expiration te ercisable	cisable on Date Expiration	7. Title Securi Deriva (Instr.	e and Amount of ties Underlying tive Security 3 and 4)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr.	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
					Code	V	(A)	(D)	LA		-uiv		J.1111 V.J		(Instr. 4)	4)	

Explanation of Responses:

- (1) The shares are held of record by The Jack Y. Zhang 2020 GRAT dated February 7, 2020, Jack Y. Zhang trustee (the "Zhang GRAT"). On February 7, 2020, Dr. Zhang contributed 353,797 shares of directly held Issuer common stock to the Zhang GRAT for the benefit of himself and his three adult children (the "Distributees"). Pursuant to the terms of the Zhang GRAT, upon termination of the Zhang GRAT, 57,365 of the shares were distributed to Distributees. The remaining 296,431 shares representing annuity payments under the Zhang GRAT were previously distributed to Dr. Zhang and continue to be reported in this Form 4 as directly owned by Dr. Zhang.
- (2) The shares are held of record by The Mary Z. Luo 2020 GRAT dated February 7, 2020, Mary Z. Luo trustee (the "Luo GRAT"). On February 7, 2020, Dr. Luo contributed 353,797 shares of directly held Issuer common stock to the Luo GRAT for the benefit of herself and her three adult children (the "Distributees"). Pursuant to the terms of the Luo GRAT, upon termination of the Luo GRAT, 57,365 of the shares were distributed to Distributees. The remaining 296,431 shares representing annuity payments under the Luo GRAT were previously distributed to Dr. Luo and continue to be reported in this

- Form 4 as directly owned by Dr. Luo.
- (3) The reported shares were withheld to satisfy the reporting person's tax liability in connection with the vesting of restricted stock units, or RSUs.
- (4) Excludes 57,365 shares previously reported as held directly by Dr. Zhang as described in footnote (1) above.
- (5) Excludes 57,365 shares previously reported as held directly by Dr. Luo as described in footnote (2) above.
- (6) The securities are held of record by Dr. Luo. The reporting persons are husband and wife.
- (7) The shares are held of record by Applied Physics & Chemistry Laboratories, Inc., of which the reporting persons and The Bill Luobei Zhang 2004 Irrevocable Trust are the sole owners.
- (8) The shares are held of record in an account for the benefit of the reporting persons' son. The reporting persons disclaim beneficial ownership of these shares, and the inclusion of these shares in this report should not be deemed an admission of beneficial ownership of any such shares for purposes of Section 16, or for any other purpose.

Reporting Owners

Reporting Owner Name / Address	Relationships							
Reporting Owner Ivallie / Address	Director	10% Owner	Officer	Other				
Zhang Jack Y. C/O AMPHASTAR PHARMACEUTICALS, INC. 11570 6TH STREET RANCHO CUCAMONGA,, CA 91730	X	X	CEO & Chief Scientific Officer					
Luo Mary Z. C/O AMPHASTAR PHARMACEUTICALS, INC. 11570 6TH STREET RANCHO CUCAMONGA., CA 91730	X	X	COO,Chief Scientist & Chairman					

Signatures

/s/ Eva Wen, by power of attorney for Jack Y. Zhang	3/20/2023		
**Signature of Reporting Person	Date		
/s/ Eva Wen, by power of attorney for Mary Z. Luo	3/20/2023		
**Signature of Reporting Person	Date		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.